bpc-157 safety regulatory status fda Legal Status: Regulations and Compounding Vincent Pedre, MD FMCP |

Cagrilintide is a synthetic, long-acting analog of human amylin (islet amyloid polypeptide) classified as a dual amylin and calcitonin receptor agonist (DACRA)

Some medical professionals tout and prescribe BPC-157 as a treatment for various conditions and injuries, including gastric ulcers, irritable bowel syndrome (this sounds plausible, given the role of natural BPC in our stomachs), ligament, tendon, and joint injuries, and erectile dysfunction

However, it is imperative to understand that fragment 176-191 (AOD-9604) does not have any effect on the level of insulin or insulin resistance

Their actual concentrations are often different from the label, and some may even contain contaminants